🟢 Cue Biopharma is trading 8% up in pre-market

Cue Biopharma is trading at $20.00, up +7.53% in pre-market; no confirmed company-specific catalyst was found.

• Positive CUE-221 Phase 2 results were announced September 20, not overnight, and are prior context rather than a confirmed explanation for the rise.
• Broader markets are under pressure after hotter-than-expected inflation, which does not explain Cue Biopharma’s upward move.
• Insider-sale reports published October 15 concern transactions made October 12; one describes the CEO’s sales as automatic tax withholding.